menu
    • menu
    [{"orgOrder":0,"company":"Danisco","sponsor":"University of Turku | 4Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Danisco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danisco \/ University of Turku | 4Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Danisco \/ University of Turku | 4Pharma"},{"orgOrder":0,"company":"Veterans Medical Research Foundation","sponsor":"National Institutes of Health | National Center for Complementary and Integrative Health | San Diego Veterans Healthcare System | University of California, San Diego","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Veterans Medical Research Foundation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Veterans Medical Research Foundation \/ National Institutes of Health | National Center for Complementary and Integrative Health | San Diego Veterans Healthcare System | University of California, San Diego","highestDevelopmentStatusID":"6","companyTruncated":"Veterans Medical Research Foundation \/ National Institutes of Health | National Center for Complementary and Integrative Health | San Diego Veterans Healthcare System | University of California, San Diego"},{"orgOrder":0,"company":"Veterans Medical Research Foundation","sponsor":"San Diego Veterans Healthcare System | National Center for Complementary and Integrative Health | University of California, San Diego | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Veterans Medical Research Foundation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Veterans Medical Research Foundation \/ San Diego Veterans Healthcare System | National Center for Complementary and Integrative Health | University of California, San Diego | National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Veterans Medical Research Foundation \/ San Diego Veterans Healthcare System | National Center for Complementary and Integrative Health | University of California, San Diego | National Institutes of Health"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"The Hershey Company","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ The Hershey Company","highestDevelopmentStatusID":"1","companyTruncated":"University of California, San Diego \/ The Hershey Company"},{"orgOrder":0,"company":"Epirium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Epirium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epirium \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Epirium \/ Undisclosed"},{"orgOrder":0,"company":"Epirium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Epirium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epirium \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Epirium \/ Undisclosed"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Epirium","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Collaboration","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Piramal Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Piramal Pharma Solutions \/ Epirium","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Pharma Solutions \/ Epirium"},{"orgOrder":0,"company":"Epirium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Epirium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epirium \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Epirium \/ Undisclosed"},{"orgOrder":0,"company":"Ralitza Gavrilova","sponsor":"Cardero Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ralitza Gavrilova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ralitza Gavrilova \/ Cardero Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Ralitza Gavrilova \/ Cardero Therapeutics"},{"orgOrder":0,"company":"Craig McDonald","sponsor":"Cardero Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Craig McDonald","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Craig McDonald \/ Cardero Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Craig McDonald \/ Cardero Therapeutics"},{"orgOrder":0,"company":"Craig McDonald","sponsor":"Cardero Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Craig McDonald","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Craig McDonald \/ Cardero Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Craig McDonald \/ Cardero Therapeutics"},{"orgOrder":0,"company":"Craig McDonald","sponsor":"Cardero Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Craig McDonald","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Craig McDonald \/ Cardero Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Craig McDonald \/ Cardero Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals for Epicatechin

    Menu

    Epicatechin

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Piramal Pharma Solutions

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Piramal Pharma Solutions

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Epirium

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Piramal Pharma Solutions to Collaborate with Epirium Bio on Exclusive Integrated Development & Manufacturing P...

                            Details : Epirium has advanced its first clinical candidate EPM-01 (Epicatechin) in Becker muscular dystrophy and plans to follow with drug development targeting other disorders associated with mitochondrial dysfunction and tissue degeneration.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Undisclosed

                            August 27, 2020

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Epirium

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Epirium

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Epirium

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Epirium Bio Announces Commencement of Phase 1 Clinical Trial of EPM-01 in Becker Muscular Dystrophy

                            Details : The Phase 1 open-label, dose-escalation study is evaluating the safety, preliminary clinical efficacy and potential biomarkers of three doses of EPM-01 in participants with Becker or Becker-like muscular dystrophy.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            August 12, 2020

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Epirium

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Epirium

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy

                            Details : Epicatechin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Muscular Dystrophy, Duchenne.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            May 13, 2020

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Epirium

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Epirium

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Epirium Bio Receives FDA Orphan-Drug Designation for EB 002 for the Treatment of Duchenne and Becker Muscular ...

                            Details : The company's prior studies have shown that EB 002 can stimulate mitochondrial biogenesis, contributing to the restoration of tissue bioenergetics, thus upregulating key protein production.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            April 14, 2020

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Craig McDonald

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Craig McDonald

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Cardero Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            (-)- Epicatechin Becker Muscular Dystrophy

                            Details : Epicatechin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Muscular Dystrophy, Duchenne.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            August 02, 2017

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Cardero Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Craig McDonald

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Craig McDonald

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Cardero Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents

                            Details : Epicatechin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Muscular Dystrophy, Duchenne.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            November 16, 2016

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Cardero Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ralitza Gavrilova

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Ralitza Gavrilova

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Cardero Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            (+) Epicatechin to Treat Friedreich's Ataxia

                            Details : Epicatechin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Friedreich Ataxia.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            January 21, 2016

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Cardero Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Veterans Medical Research Foundation

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Veterans Medical Research Foundation

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : San Diego Veterans Healthcare System | National Center for Complementary and Integrative Health | University of California, San Diego | National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin (Part 2)

                            Details : Epicatechin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            January 14, 2016

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : San Diego Veterans Healthcare System | National Center for Complementary and Integrative Health | University of California, San Diego | National Institutes of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Veterans Medical Research Foundation

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Veterans Medical Research Foundation

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : National Institutes of Health | National Center for Complementary and Integrative Health | San Diego Veterans Healthcare System | University of California, San Diego

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin

                            Details : Epicatechin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            January 01, 2015

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : National Institutes of Health | National Center for Complementary and Integrative Health | San Diego Veterans Healthcare System | University of California, San Diego

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Craig McDonald

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Craig McDonald

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Cardero Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)

                            Details : Epicatechin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Muscular Dystrophy, Duchenne.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            May 17, 2013

                            Lead Product(s) : Epicatechin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Cardero Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth